Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer

This study tests whether adding sodium valproate — a drug commonly used for epilepsy — to standard targeted antibody therapy (cetuximab or panitumumab) improves outcomes for people with metastatic colorectal cancer that cannot be surgically removed. **You may be eligible if...** - You are 18 or older with colorectal cancer that has spread and cannot be cured by surgery - Your cancer has a specific genetic profile called RAS wild type (meaning it lacks certain mutations) - You have completed about 4 months of first-line chemotherapy and your cancer responded or stabilized - You are well enough to carry out daily activities (ECOG 0 or 1) **You may NOT be eligible if...** - Your cancer has RAS mutations - You are already on valproate or have a history of valproate-related complications - You have severe liver problems - You are pregnant or breastfeeding - You have uncontrolled other medical conditions Talk to your doctor to see if this trial is right for you.